Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
MicroRNAs01:22

MicroRNAs

3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The Impact of Staging Investigations in HER2-Low, Low-Risk Patients.

Breast care (Basel, Switzerland)·2026
Same author

Effects of quetiapine on cognitive functioning in schizophrenia: evidence for the remyelination hypothesis?

European archives of psychiatry and clinical neuroscience·2026
Same author

Knowledge About Psychosocial Interventions Among Individuals With Severe Mental Illness: Results of a Cross-Sectional Study.

Community mental health journal·2026
Same author

Assessment of breast cancer and feasibility of subtyping of breast cancer using thoracoabdominal staging photon-counting detector computed tomography.

Scientific reports·2026
Same author

Real-World Assessment of Prophylactic Anakinra on Neurotoxicity and Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory B-Cell Lymphoma: An Inverse Probability of Treatment Weighting Analysis.

Transplantation and cellular therapy·2026
Same author

Divergent Resilience of Bacterial and Fungal Gut Microbiota After Colorectal Surgery: Insights From a Prospective Longitudinal Cohort Study.

MedComm·2026

相关实验视频

Updated: Jul 12, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

在乳腺癌中CDK4/6治疗下体外微RNA表达特征的改变.

Jasmin Asberger1,2, Kai Berner1,2, Anna Bicker1,2,3

  • 1Department of Obstetrics and Gynecology, Medical Center-University Hospital Freiburg, 79106 Freiburg, Germany.

Biomedicines
|October 28, 2023
PubMed
概括
此摘要是机器生成的。

微RNA可以预测乳腺癌治疗反应. 细胞外微RNAs miR-100,miR-10b和miR-182在循环素依赖激酶 (CDK) 抑制下显示为治疗反应的循环生物标志物.

关键词:
这是一种CDK抑制剂.乳腺癌 乳腺癌 乳腺癌循环中的微RNAs.疾病生物标志物疾病生物标志物微RNAs 是一个微型RNA.这是palbocicliblib.治疗反应治疗反应的治疗.尿路中的微RNAs.

更多相关视频

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.3K
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

6.8K

相关实验视频

Last Updated: Jul 12, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.3K
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

6.8K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 生物标志物发现发现

背景情况:

  • 乳腺癌是全球领先的癌症,循环林依赖激酶 (CDK) 抑制剂是转移性治疗的基石.
  • 治疗失败是常见的,需要新的策略来预测治疗反应.
  • 微RNAs (miRNAs) 正在作为治疗疗效的潜在生物标志物进行研究.

研究的目的:

  • 评估特定微RNAs (miRNAs) 的生物标志物潜力,以预测乳腺癌治疗反应.
  • 在palbociclib和letrozole治疗下分析miRNA表达变化.

主要方法:

  • 对56种miRNA的细胞内和细胞外miRNA表达水平的分析.
  • 在乳腺癌细胞系 (BT-474,MCF-7,HS-578T) 上利用定量聚合酶链反应 (qPCR).
  • 在palbociclib单一治疗和与莱特醇联合治疗下研究的miRNA变化.

主要成果:

  • 一个独特的palbociclib诱导的miRNA签名被确定在细胞内和细胞外.
  • 细胞内miRNAs (miR-10a,miR-15b,miR-21,miR-23a,miR-23c) 在细胞系中显示出一致的调节.
  • 细胞外的miRNAs (miR-100,miR-10b,miR-182) 得到了一致的调节,miR-17在激素受体阳性细胞中显示出特定的调节.

结论:

  • 细胞外miRNAsmiR-100,miR-10b和miR-182是有希望的循环生物标志物,可以预测由于它们的分泌和上调,对CDK抑制剂的治疗反应.
  • 细胞内miRNAsmiR-10a,miR-15b,miR-21,miR-23a和miR-23c代表了评估治疗反应的潜在基于组织的生物标志物.